Omnicell reports Q2 non-GAAP EPS 45c, consensus 27c

Reports Q2 revenue $291M, consensus $275.24M. “We are pleased to deliver another quarter of strong financial performance, with total revenues, non-GAAP EPS and non-GAAP EBITDA for second quarter 2025 all exceeding the upper end of our previously provided guidance,” said CEO Randall Lipps. “During the quarter, we saw broad demand across our range of solutions, with notable strength coming from our point-of-care connected devices, including our XT Series automated dispensing cabinets and the XTExtend console, a part of our XT Amplify program. In parallel, we continued to work to drive the innovation that our customers have come to expect, most recently with the introduction of our MedTrack RFID Line and MedVision inventory management solution. Our unwavering focus on improving clinical and operational outcomes guides everything we do at Omnicell (OMCL), and we believe that this continues to resonate with current and prospective customers across the entire continuum of care.”